Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive strategies against SARS-CoV-2 in kidney transplant recipients
2021-002927-39Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- May 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of Ad26.COV2.S, ChAdOx1 nCoV-19 and tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Medical University of Vienna. Primary endpoint: Primary immunological response endpoint. Started May 2021; status: completed.
02
Drugs
Ad26.COV2.SChAdOx1 nCoV-19tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002927-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002927-39.